Johnson & Johnson (NYSE:JNJ) Stock Price Down 1.5% – Should You Sell?

06 Jan 2026, 01:27 by Kim Johansen · The Markets Daily

Johnson & Johnson (NYSE:JNJ – Get Free Report)’s share price traded down 1.5% during mid-day trading on Monday . The company traded as low as $200.91 and last traded at $204.3160. 9,156,520 shares traded hands during trading, an increase of 18% from the average session volume of 7,731,133 shares. The stock had previously closed at $207.35.

Analyst Ratings Changes

Several equities analysts have issued reports on JNJ shares. Guggenheim boosted their target price on Johnson & Johnson from $206.00 to $227.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday, October 15th. Wells Fargo & Company raised their target price on Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Wolfe Research lifted their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a report on Monday. Finally, UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Monday. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $212.62.

View Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Trading Down 1.5%

The business has a 50 day simple moving average of $201.17 and a two-hundred day simple moving average of $183.07. The stock has a market cap of $492.26 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 2.13 and a beta of 0.34. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at $26,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at $28,000. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson during the second quarter valued at about $27,000. Semmax Financial Advisors Inc. lifted its holdings in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the last quarter. Finally, Turning Point Benefit Group Inc. bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $41,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.